A novel class of drugs to treat cancer | Aura Biosciences Bel-sar ComPass Trial

A novel class of drugs to treat cancer | Aura Biosciences Bel-sar ComPass Trial
🔬Discover the groundbreaking journey with Aura Biosciences' as they work to develop a novel class of targeted oncology drugs for multiple cancer indications, including for the primary treatment of ocular melanoma. In this episode of the Eye Believe Podcast, we dive deep with Eli de los Pinos, founder and CEO of Aura Biosciences, exploring the cutting-edge advancements in treating ocular melanoma and beyond.
🌟 Eli shares her passionate journey from a scientist to an entrepreneur, driven to develop transformative drugs that offer hope without compromise. Learn how their novel approach aims to prime the immune system's T-cells to become vigilant warriors against cancer cells, offering a potential treatment that's both effective and preserves quality of life, as well as vision in the eye.
👁️‍🗨️ What You'll Discover:
The inspiring story behind Aura Biosciences and its mission to innovate cancer treatments. An in-depth look at their first-of-its-kind therapy that targets ocular melanoma cancer with precision. Insights into the future of cancer care and how Aura Biosciences is leading the charge in ocular oncology as the envision a new way to treat cancer.. Join us as we explore the exciting possibilities of this novel therapy in the fight against cancer, shedding light on the science, the strategy, and the stories of hope it brings to patients worldwide. ✨ Subscribe for more updates on groundbreaking medical advancements and stories of innovation in the battle against cancer.
📌 Learn More About Aura Biosciences & Ongoing Clinical Trials:
aurabiosciences.com/contact/
classic.clinicaltrials.gov/ct...
Social Media Handles:
Twitter/X: @AuraBiosciences / aurabiosciences
LinkedIn: Aura Biosciences / aurabiosciences
Elisabet de los Pinos / elidelospinos
#CancerCure #TCellTherapy #OcularMelanoma #AuraBioSciences #MedicalInnovation #EyeBelievePodcast